Maisie has 2 copies of SMN2 gene
Treated at 20 months old

Before receiving treatment with ZOLGENSMA, 
Maisie received another SMA treatment.

The safety of ZOLGENSMA has been evaluated in 4 clinical trials

ZOLGENSMA^® (onasemnogene abeparvovec-xioi) has safety results from prospective open-label clinical trials and an observational long-term follow-up (LTFU) study.

A total of 44 patients were treated with ZOLGENSMA and ranged in age from 0.3 to 7.9 months at the time of infusion.

Children can experience side effects with ZOLGENSMA. It’s important to plan to manage them with your health care team. The most frequently experienced adverse reactions (incidence ≥5%) were elevated liver enzymes and vomiting. Reports of thrombotic microangiopathy (TMA), thrombocytopenia, acute liver injury or failure that could result in death, pyrexia (or fever), infusion-related reactions, and increased troponin were identified after ZOLGENSMA became available to the public. Other side effects may be possible. For more information on the safety profile of ZOLGENSMA, please reach out to your doctor.